Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Dosing of vancomycin in patients with continuous-flow left ventricular assist devices: a clinical pharmacokinetic analysis.

Jennings DL, Makowski CT, Chambers RM, Lanfear DE.

Int J Artif Organs. 2014 Mar;37(3):270-4. doi: 10.5301/ijao.5000285. Epub 2014 Jan 16.

2.

Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections.

Adane ED, Herald M, Koura F.

Pharmacotherapy. 2015 Feb;35(2):127-39. doi: 10.1002/phar.1531. Epub 2015 Feb 3.

PMID:
25644478
3.

Correlation of aminoglycoside and vancomycin pharmacokinetic parameters.

Wragge TM, Cooper BE.

Ann Pharmacother. 1993 Nov;27(11):1346-8.

PMID:
8286806
4.

Initial dosage regimens of vancomycin for Chinese adult patients based on population pharmacokinetic analysis.

Deng C, Liu T, Zhou T, Lu H, Cheng D, Zhong X, Lu W.

Int J Clin Pharmacol Ther. 2013 May;51(5):407-15. doi: 10.5414/CP201842.

PMID:
23458230
5.

Characterization of vancomycin pharmacokinetics in the adult acute myeloid leukemia population.

Jarkowski A 3rd, Forrest A, Sweeney RP, Tan W, Segal BH, Almyroudis N, Wang ES, Wetzler M.

J Oncol Pharm Pract. 2012 Mar;18(1):91-6. doi: 10.1177/1078155211402107. Epub 2011 Apr 26.

PMID:
21521799
6.

Vancomycin pharmacokinetics and dosing in premature neonates.

McDougal A, Ling EW, Levine M.

Ther Drug Monit. 1995 Aug;17(4):319-26.

PMID:
7482683
7.

Vancomycin clearance during continuous venovenous haemofiltration in critically ill patients.

Boereboom FT, Ververs FF, Blankestijn PJ, Savelkoul TJ, van Dijk A.

Intensive Care Med. 1999 Oct;25(10):1100-4.

PMID:
10551965
8.
9.

Vancomycin Dosing Considerations in a Real-World Cohort of Obese and Extremely Obese Patients.

Morrill HJ, Caffrey AR, Noh E, LaPlante KL.

Pharmacotherapy. 2015 Sep;35(9):869-75. doi: 10.1002/phar.1625. Epub 2015 Sep 6.

PMID:
26343549
10.

Vancomycin dosing: assessment of time to therapeutic concentration and predictive accuracy of pharmacokinetic modeling software.

Nunn MO, Corallo CE, Aubron C, Poole S, Dooley MJ, Cheng AC.

Ann Pharmacother. 2011 Jun;45(6):757-63. doi: 10.1345/aph.1P634. Epub 2011 Jun 7.

PMID:
21652786
11.

Population pharmacokinetics of intermittent vancomycin in children with cystic fibrosis.

Stockmann C, Sherwin CM, Zobell JT, Lubsch L, Young DC, Olson J, Noyes BE, Ampofo K, Spigarelli MG.

Pharmacotherapy. 2013 Dec;33(12):1288-96. doi: 10.1002/phar.1320. Epub 2013 Jul 3.

PMID:
23824677
12.

Dosage adjustments for antibacterials in obese patients: applying clinical pharmacokinetics.

Bearden DT, Rodvold KA.

Clin Pharmacokinet. 2000 May;38(5):415-26. Review.

PMID:
10843460
13.

Can population pharmacokinetic modelling guide vancomycin dosing during continuous renal replacement therapy in critically ill patients?

Udy AA, Covajes C, Taccone FS, Jacobs F, Vincent JL, Lipman J, Roberts JA.

Int J Antimicrob Agents. 2013 Jun;41(6):564-8. doi: 10.1016/j.ijantimicag.2013.01.018. Epub 2013 Mar 6.

PMID:
23473944
14.

Aminoglycoside pharmacokinetics in African-Americans with normal renal function.

Oparaoji EC, Siram S, Elemihe U, Mezghebe HM, Cho T, Bashiri M, Piedrahita K, Pipalla RS.

J Clin Pharm Ther. 1998 Jun;23(3):191-7.

PMID:
9831970
15.

Optimal dose of vancomycin for treating methicillin-resistant Staphylococcus aureus pneumonia in critically ill patients.

Chung J, Oh JM, Cho EM, Jang HJ, Hong SB, Lim CM, Koh YS.

Anaesth Intensive Care. 2011 Nov;39(6):1030-7.

16.

Systemic inflammatory response syndrome criteria and vancomycin dose requirement in patients with sepsis.

Shimamoto Y, Fukuda T, Tanaka K, Komori K, Sadamitsu D.

Intensive Care Med. 2013 Jul;39(7):1247-52. doi: 10.1007/s00134-013-2909-9. Epub 2013 Apr 20.

PMID:
23604132
17.

Decreased vancomycin clearance in patients with congestive heart failure.

Shimamoto Y, Fukuda T, Tominari S, Fukumoto K, Ueno K, Dong M, Tanaka K, Shirasaka T, Komori K.

Eur J Clin Pharmacol. 2013 Mar;69(3):449-57. doi: 10.1007/s00228-012-1340-4. Epub 2012 Jul 12.

PMID:
22791272
18.

Infectious complications in patients with left ventricular assist device: etiology and outcomes in the continuous-flow era.

Topkara VK, Kondareddy S, Malik F, Wang IW, Mann DL, Ewald GA, Moazami N.

Ann Thorac Surg. 2010 Oct;90(4):1270-7. doi: 10.1016/j.athoracsur.2010.04.093.

PMID:
20868826
19.

Pharmacokinetics of vancomycin and dosing recommendations for trauma patients.

Medellín-Garibay SE, Ortiz-Martín B, Rueda-Naharro A, García B, Romano-Moreno S, Barcia E.

J Antimicrob Chemother. 2016 Feb;71(2):471-9. doi: 10.1093/jac/dkv372. Epub 2015 Nov 14.

PMID:
26568565
20.

Population pharmacokinetics and dosing optimization of vancomycin in children with malignant hematological disease.

Zhao W, Zhang D, Fakhoury M, Fahd M, Duquesne F, Storme T, Baruchel A, Jacqz-Aigrain E.

Antimicrob Agents Chemother. 2014 Jun;58(6):3191-9. doi: 10.1128/AAC.02564-13. Epub 2014 Mar 24.

Supplemental Content

Support Center